Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Other Accumulated Expenses (2023 - 2025)

Historic Other Accumulated Expenses for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $15.6 million.

  • Immunome's Other Accumulated Expenses fell 1373.64% to $15.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.6 million, marking a year-over-year decrease of 1373.64%. This contributed to the annual value of $24.2 million for FY2024, which is 124810.48% up from last year.
  • Immunome's Other Accumulated Expenses amounted to $15.6 million in Q3 2025, which was down 1373.64% from $10.6 million recorded in Q2 2025.
  • Immunome's Other Accumulated Expenses' 5-year high stood at $24.2 million during Q4 2024, with a 5-year trough of $713000.0 in Q3 2023.
  • For the 3-year period, Immunome's Other Accumulated Expenses averaged around $9.8 million, with its median value being $10.6 million (2025).
  • As far as peak fluctuations go, Immunome's Other Accumulated Expenses surged by 243520.34% in 2024, and later crashed by 2694.7% in 2025.
  • Quarter analysis of 3 years shows Immunome's Other Accumulated Expenses stood at $1.8 million in 2023, then skyrocketed by 1248.1% to $24.2 million in 2024, then crashed by 35.53% to $15.6 million in 2025.
  • Its Other Accumulated Expenses was $15.6 million in Q3 2025, compared to $10.6 million in Q2 2025 and $12.5 million in Q1 2025.